Cargando…

SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?

Disclosure: L. Orioli: None. S. Samaras: None. P. Lause: None. M. de Barsy: None. J.M. Thissen: None. A. Loumaye: None. Rationale: Our study aims to determine whether myostatin is a biomarker of muscle mass in cancer cachexia and obesity. Methods: The ACTICA study included cancer patients with and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Orioli, Laura, Samaras, Sofia, Lause, Pascale, de Barsy, Marie, Thissen, Jean-Paul Mathieu, Loumaye, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554282/
http://dx.doi.org/10.1210/jendso/bvad114.118
_version_ 1785116375314857984
author Orioli, Laura
Samaras, Sofia
Lause, Pascale
de Barsy, Marie
Thissen, Jean-Paul Mathieu
Loumaye, Audrey
author_facet Orioli, Laura
Samaras, Sofia
Lause, Pascale
de Barsy, Marie
Thissen, Jean-Paul Mathieu
Loumaye, Audrey
author_sort Orioli, Laura
collection PubMed
description Disclosure: L. Orioli: None. S. Samaras: None. P. Lause: None. M. de Barsy: None. J.M. Thissen: None. A. Loumaye: None. Rationale: Our study aims to determine whether myostatin is a biomarker of muscle mass in cancer cachexia and obesity. Methods: The ACTICA study included cancer patients with and without cachexia. The MYDIASECRET study included obese patients evaluated before and 3 months after bariatric surgery. Body composition was assessed using bioelectrical impedance analysis (BIA101 device, Akern). Skeletal muscle mass (SMM) and appendicular SMM (ASMM) were calculated from Janssen’s and Sergi’s equations, respectively. Results were expressed as indexes (kg/m²). Myostatin plasma concentrations were determined using ELISA. Spearman’s coefficient was used to correlate muscle mass indexes and myostatin. Results: The ACTICA study included 143 patients of whom 70 with cachexia. SMM index (SMMI) and ASMM index (ASMMI) were lower in patients with cachexia compared to those without cachexia (SMMI: 8.0 kg/m² [6.7-9.5] vs 9.0 kg/m² [7.8-10.1], p=0.004; ASMMI: 6.2 kg/m² [5.5-7.1] vs 7.2 kg/m² [6.4-7.8], p<0.001). Myostatin was also lower in patients with cachexia (1434 pg/mL [999-2118] vs 2149 pg/mL [1551-2984], p<0.001). Myostatin was positively correlated with SMMI and ASMMI (SMMI: R=0.500, p<0.001; ASMMI: R=0.479, p<0.001). The MYDIASECRET study included 62 patients. SMMI and ASMMI were decreased after surgery (SMMI: -0.8 kg/m², p<0.001; ASMMI: -1.1 kg/m², p<0.001). Myostatin was also decreased after surgery (1773 pg/mL [1440-2309] vs 2582 pg/mL [1708-3522], p<0.001). Myostatin was positively correlated with SMMI before (R=0.388, p=0.002) and after surgery (R=0.435, p<0.001). Change in myostatin after surgery was also positively correlated with change in SSMI (R=0.287, p=0.023). Conclusion: Myostatin is positively correlated with muscle mass indexes in different conditions, suggesting its potential role as a biomarker of muscle mass. Presentation: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10554282
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105542822023-10-06 SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass? Orioli, Laura Samaras, Sofia Lause, Pascale de Barsy, Marie Thissen, Jean-Paul Mathieu Loumaye, Audrey J Endocr Soc Adipose Tissue, Appetite, & Obesity Disclosure: L. Orioli: None. S. Samaras: None. P. Lause: None. M. de Barsy: None. J.M. Thissen: None. A. Loumaye: None. Rationale: Our study aims to determine whether myostatin is a biomarker of muscle mass in cancer cachexia and obesity. Methods: The ACTICA study included cancer patients with and without cachexia. The MYDIASECRET study included obese patients evaluated before and 3 months after bariatric surgery. Body composition was assessed using bioelectrical impedance analysis (BIA101 device, Akern). Skeletal muscle mass (SMM) and appendicular SMM (ASMM) were calculated from Janssen’s and Sergi’s equations, respectively. Results were expressed as indexes (kg/m²). Myostatin plasma concentrations were determined using ELISA. Spearman’s coefficient was used to correlate muscle mass indexes and myostatin. Results: The ACTICA study included 143 patients of whom 70 with cachexia. SMM index (SMMI) and ASMM index (ASMMI) were lower in patients with cachexia compared to those without cachexia (SMMI: 8.0 kg/m² [6.7-9.5] vs 9.0 kg/m² [7.8-10.1], p=0.004; ASMMI: 6.2 kg/m² [5.5-7.1] vs 7.2 kg/m² [6.4-7.8], p<0.001). Myostatin was also lower in patients with cachexia (1434 pg/mL [999-2118] vs 2149 pg/mL [1551-2984], p<0.001). Myostatin was positively correlated with SMMI and ASMMI (SMMI: R=0.500, p<0.001; ASMMI: R=0.479, p<0.001). The MYDIASECRET study included 62 patients. SMMI and ASMMI were decreased after surgery (SMMI: -0.8 kg/m², p<0.001; ASMMI: -1.1 kg/m², p<0.001). Myostatin was also decreased after surgery (1773 pg/mL [1440-2309] vs 2582 pg/mL [1708-3522], p<0.001). Myostatin was positively correlated with SMMI before (R=0.388, p=0.002) and after surgery (R=0.435, p<0.001). Change in myostatin after surgery was also positively correlated with change in SSMI (R=0.287, p=0.023). Conclusion: Myostatin is positively correlated with muscle mass indexes in different conditions, suggesting its potential role as a biomarker of muscle mass. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554282/ http://dx.doi.org/10.1210/jendso/bvad114.118 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adipose Tissue, Appetite, & Obesity
Orioli, Laura
Samaras, Sofia
Lause, Pascale
de Barsy, Marie
Thissen, Jean-Paul Mathieu
Loumaye, Audrey
SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title_full SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title_fullStr SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title_full_unstemmed SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title_short SAT670 Is Myostatin A Biomarker Of Skeletal Muscle Mass?
title_sort sat670 is myostatin a biomarker of skeletal muscle mass?
topic Adipose Tissue, Appetite, & Obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554282/
http://dx.doi.org/10.1210/jendso/bvad114.118
work_keys_str_mv AT oriolilaura sat670ismyostatinabiomarkerofskeletalmusclemass
AT samarassofia sat670ismyostatinabiomarkerofskeletalmusclemass
AT lausepascale sat670ismyostatinabiomarkerofskeletalmusclemass
AT debarsymarie sat670ismyostatinabiomarkerofskeletalmusclemass
AT thissenjeanpaulmathieu sat670ismyostatinabiomarkerofskeletalmusclemass
AT loumayeaudrey sat670ismyostatinabiomarkerofskeletalmusclemass